Date: 2016-10-11
Type of information: Licensing agreement
Compound: bispecific antibodies
Company: Kymab (UK) EpimAb Biotherapeutics (China)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: bispecific antibody
Disease:
Details: * On October 11, 2016, Kymab, a leading human monoclonal antibody biopharmaceutical company, and EpimAb Biotherapeutics, an emerging biopharmaceutical company specializing in bispecific antibodies, announced a cross-licensing and development agreement to develop bispecific therapeutic antibodies against multiple targets. The parties will focus their efforts on immuno-oncology and will combine EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig™) platform to generate multiple bispecific antibodies combined with antibodies sourced from Kymab’s proprietary Kymouse™ platform.
EpimAb’s innovative FIT-Ig™ technology offers a novel approach for generating bispecific antibodies, with the resulting molecules fully retaining the biological properties of their parental monoclonal antibodies without the need to significantly modify the basic structural elements of the bispecificantibody. FIT-Ig™ molecules generated to date have demonstrated excellent biological and pharmacological characteristics, as well as excellent physical-chemical properties. The combination of Kymab’s Kymouse™ human antibody discovery platform with the FIT-Ig™ technology will assure the highest probability of finding the best-in-class bispecific antibodies with highly attractive drug properties.
Financial terms: Kymab will have the development and commercialization rights to these bispecificsin all geographical regions outside of China, and, under the terms of the cross license agreement, EpimAb will have the rights for the China market. Each party is eligible to receive milestone payments and royalties for development programs pursued by the other party.
Latest news:
